We provide the latest news
from the world of economics and finance
(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) Thursday announced that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has recommended marketing authorization for its Omicron JN.1-adapted monovalent COVID-19 vaccine for active immunization.
This drug is intended to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the World Health Organization's Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency's Emergency Task Force.
The European Commission will review the CHMP's recommendation and will make a final decision.
The CHMP's recommendation is based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the COVID-19 vaccines by Pfizer and BioNTech.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.